|
|
Article: Metastatix Targeting CXCR4 Receptors In Cancer, HIV.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
With the recent completion of a $3.6 million Series A round, start-up firm Metastatix Inc. is ready to move toward the clinic with its first program, a chemokine inhibitor designed to prevent tumor growth and cancer metastasis by blocking the CXCR4 receptor.
The financing, led by Atlanta-based H.I.G. Ventures, is expected to "take us up to filing an investigational new drug application," said Metastatix President and CEO Tony Shuker, who, along with Dennis Liotta, Mike Natchus, Jim Snyder and Hyansuk Shim, founded the company last year as a spin-out of Emory University in Atlanta.
Emory licensed to Metastatix the initial technology ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|